The ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop is sponsored by the ASA Biopharmaceutical Section in cooperation with the FDA Statistical Association. Each year 800 statistical practitioners come together to absorb new information on statistical practices in all areas regulated by the FDA.
Cytel was honored to be involved in the workshop program, and our subject matter experts added value to the conference by sharing their academic and regulatory experiences.
Don’t worry if you missed the event!
In this blog, we share the full slide set slide from Cytel contributions at the ASA Biopharmaceutical Section Regulatory Industry Statistics Workshop.
Sample Size Re-Estimation: Controlling the Type-1 Error - Yannis Jemiai
Yannis Jemiai addresses uncertainty in trial design assumptions. He then analyzes one of the most popular adaptations, especially when using a promising zone approach.
Bayesian Study Design to Leverage Informative Prior Information - Jim Bolognese and Sam Hsiao
Efficiency Promising of Zone Designs - Cyrus Mehta, Sam Hsiao and Lingyun Liu
With promising zone designs, efficiency is in the eye of the beholder. Depending on the type of SSR rule adopted, an adaptive design may suffer a small power loss at the design stage. But if the interim results are promising, then this will be more than compensated for at the interim monitoring stage.
PS4b Parallell Session - Caroline Morgan
Shared DIA, FDA, and EMA perspectives on the uptake and application of adaptive designs across the industry.
Liked this? Click the button below to join our community of biopharma innovators and sign up for Cytel blog updates direct to your inbox.